{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:33:32Z","timestamp":1783578812062,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":964,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.jval.2010.10.016","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T12:39:47Z","timestamp":1299587987000},"page":"15-23","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis"],"prefix":"10.1016","volume":"14","author":[{"given":"Ewen","family":"Cummins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Asseburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh Suresh","family":"Punekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2010.10.016_bib1","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2010.10.016_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jval.2010.10.016_bib3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1067\/mjd.2002.119669","article-title":"The direct cost of care for psoriasis and psoriatic arthritis in the United States","volume":"46","author":"Javitz","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jval.2010.10.016_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/ard.2005.046367","article-title":"Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany","volume":"65","author":"Huscher","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2010.10.016_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/keh514","article-title":"Guideline for anti-TNF-\u03b1 therapy in psoriatic arthritis","volume":"44","author":"Kyle","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2010.10.016_bib6","first-page":"1417","article-title":"Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2010.10.016_bib7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2010.10.016_bib8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"4","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2010.10.016_bib9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/rheumatology\/kem221","article-title":"The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis","volume":"46","author":"Bravo Vergel","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jval.2010.10.016_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","article-title":"Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden","volume":"61","author":"Geborek","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2010.10.016_bib11","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2010.10.016_bib12","series-title":"Infliximab for the treatment of adults with psoriasis","year":"2008"},{"key":"10.1016\/j.jval.2010.10.016_bib13","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/art.10471","article-title":"Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis","volume":"46","author":"Kobelt","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2010.10.016_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0272989X05284108","article-title":"Estimating the association between SF-12 responses and EQ-5D utility values by response mapping","volume":"26","author":"Gray","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2010.10.016_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2010.10.016_bib16","series-title":"Guide to the methods of technology appraisal","year":"2008"},{"key":"10.1016\/j.jval.2010.10.016_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kel147","article-title":"Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis","volume":"45","author":"Bansback","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jval.2010.10.016_bib18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/ken320","article-title":"The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy","volume":"47","author":"Olivieri","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jval.2010.10.016_bib19","series-title":"Etanercept and infliximab for the treatment of adults with psoriatic arthritis","year":"2006"},{"key":"10.1016\/j.jval.2010.10.016_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2010.10.016_bib21","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2010.10.016_bib22","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2010.10.016_bib23","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2010.10.016_bib25","series-title":"Final appraisal determination: etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review of technology appraisal guidance 104 and 125)","year":"2010"},{"key":"10.1016\/j.jval.2010.10.016_bib26","series-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","author":"Rodgers","year":"2009"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T04:23:24Z","timestamp":1543897404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1098301510000173"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2010.10.016","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}